ANI Pharmaceuticals (NASDAQ:ANIP) Announces Quarterly Earnings Results, Beats Estimates By $0.22 EPS

ANI Pharmaceuticals (NASDAQ:ANIP) announced its quarterly earnings results on Friday. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.41 by $0.22, RTT News reports. The company had revenue of $190.60 million for the quarter, compared to the consensus estimate of $175.36 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals’s revenue for the quarter was up 44.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.04 EPS. ANI Pharmaceuticals updated its FY25 guidance to $6.12-6.49 EPS.

ANI Pharmaceuticals Trading Up 13.1 %

NASDAQ ANIP traded up $7.13 on Friday, hitting $61.71. 378,009 shares of the stock were exchanged, compared to its average volume of 200,808. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $70.81. The firm has a market capitalization of $1.30 billion, a P/E ratio of -112.31 and a beta of 0.74. The stock has a fifty day moving average price of $57.06 and a two-hundred day moving average price of $58.13.

Insider Activity

In related news, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at approximately $2,943,540. This represents a 2.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the sale, the chief financial officer now directly owns 154,468 shares in the company, valued at $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,300 shares of company stock valued at $584,009. 12.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ANIP. StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price for the company. Finally, Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $77.71.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.